News Releases

Jan 05, 2023
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Products
Jan 04, 2023
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Corporate
Dec 19, 2022
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
Corporate
Dec 08, 2022
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Products
Nov 29, 2022
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Products
Nov 17, 2022
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Products
Nov 14, 2022
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
Products
Nov 10, 2022
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
Products
Nov 03, 2022
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Products
Nov 01, 2022
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
Pipeline
Nov 01, 2022
Myriad Genetics Reports Third Quarter Financial Results
Financial
Oct 31, 2022
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
Corporate
Oct 26, 2022
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
Financial
Sep 28, 2022
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
Corporate
Aug 31, 2022
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
Products